Oxovasin® activates the wound macrophages in order to enable their key functions in all three phases of wound healing:
- Wound cleansing with defence against infection
- Wound granulation with the formation of new vessels and wound tissue
- Wound closure
Principle of wound treatment with Oxovasin®
Oxovasin® penetrates through the wound and the wound borders into the regenerative tissue layers, stimulates thereabouts the cellular defense, and resolves excessive inflammation reactions in the wound.
Oxovasin® stimulates the macrophages leading to effective defense against infection. Since the wound cleaning processes start from the wound ground, changes to the wound surface need not necessarily be evident at first. The disintegration of necroses (dead tissue) and the simultaneous start of the formation of connective tissue containing plenty of vessels (granulation) are characteristic of wounds treated with Oxovasin®.
Next to wound cleansing and fighting against infections, the stimulation of the macrophages results in the secretion of factors for tissue regeneration and the formation of new vessels. The aqueous solution Oxovasin® supports the humid environment of the wound.
By forming clean, healthy granulation tissue with good blood circulation, Oxovasin® generates the requirements for rapidly visible wound closure with good cicatrisation (scar formation).
Clinical trials demonstrating the efficacy of Oxovasin®
Oxovasin® has been used successfully for more than 20 years for the treatment of badly healing wounds. Its effectiveness has been impressively demonstrated in several clinical trials involving more than 8,000 documented cases.
Among others, the efficacy of Oxovasin® was demonstrated in clinical trial conducted 1986 at a number of German hospitals. The results of this study were published in the famous medical journal The Lancet*. The investigator’s assessment with respect to wound cleansing, granulation, and the degree of epitheliization was statistically significant to highly significant better within the Oxovasin® group (137 patients) compared to the assessment of the patients in the control group (134 patients), who had been treated with physiological saline solution. Moreover, the results of the objective assessment parameters wound contraction (measured using three-dimensional planimetry) and the microbial count in the wound were significantly better in the Oxovasin® group compared to the control group.
Other clinical trials have demonstrated the effectiveness of Oxovasin® in connection with severe wound healing disorders that could either not or barely be therapeutically controlled by other wound healing agents available at that time, such as damage to the skin and mucous membrane caused by radiotherapy or chemotherapy.
We are pleased to provide on request additional information to professional interested parties (physicians, pharmacists).
*) Hinz, J., Hautzinger, H., Stahl, K. W.,
Rationale for and results from a randomised double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Lancet, April 12, 825–828 (1986) (name of Oxovasin® at that time: TCDO solution, Oxoferin)